Platelets, immune-mediated thrombocytopenias, and fetal hemorrhage

Thrombosis Research

Volumn 141, Issue , 2016, Pages S76-S79

  Xu, Xiaohong Ruby ^a,b,c,d   Gallant, Reid C ^a,b,c   Ni, Heyu ^a,b,c,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b Toronto Platelet Immunobiology Group   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^e CANADIAN BLOOD SERVICES   (Canada)

Author keywords

fibrinogen; fibronectin; immune mediated thrombocytopenia; integrins; Platelet; thrombosis

Indexed keywords

FC RECEPTOR; FIBRINOGEN; FIBRONECTIN; PHOSPHATIDYLSERINE; RECEPTOR ANTIBODY; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD CLOTTING; FETAL HEMORRHAGE; FETUS; HEMOSTASIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTOPENIA; ANIMAL; BLEEDING; BLOOD; IMMUNITY; IMMUNOLOGY; PATHOLOGY; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; HEMORRHAGE; HEMOSTASIS; HUMANS; IMMUNITY; THROMBOCYTOPENIA; THROMBOSIS;

EID: 84989895722     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(16)30372-3     Document Type: Article

References (50)

1. 1 Junt, T, Schulze, H, Chen, Z, et al. Dynamic visualization of thrombopoiesis within bone marrow. Science 317:5845 (2007), 1767–1770.
2. 2 Ruggeri, ZM, Platelets in atherothrombosis. Nature medicine 8:11 (2002), 1227–1234.
3. 3 Li, C, Li, J, Li, Y, et al. Crosstalk between Platelets and the Immune System: Old Systems with New Discoveries. Advances in hematology 2012 (2012), 384–685.
4. 4 Murphy, AJ, Bijl, N, Yvan-Charvet, L, et al. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nature medicine 19:5 (2013), 586–594.
5. 5 Semple, JW, Italiano, JE Jr., Freedman, J, Platelets and the immune continuum. Nat Rev Immunol 11:4 (2011), 264–274.
6. 6 Ruggeri, ZM, Mechanisms initiating platelet thrombus formation. Thromb Haemost 78:1 (1997), 611–616.
7. 7 Wang, Y, Reheman, A, Spring, CM, et al. Plasma fibronectin supports hemostasis and regulates thrombosis. J Clin Invest 124:10 (2014), 4281–4293.
8. 8 Hou, Y, Carrim, N, Wang, Y, et al. Platelets in hemostasis and thrombosis: Novel mechanisms of fibrinogen-independent platelet aggregation and fibronectin-mediated protein wave of hemostasis. Journal of biomedical research 29:6 (2015), 437–444.
9. 9 Lei, X, Reheman, A, Hou, Y, et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 111:2 (2014), 279–289.
10. 10 Jackson, SP, The growing complexity of platelet aggregation. Blood 109:12 (2007), 5087–5095.
11. 11 Ni, H, Freedman, J, Platelets in hemostasis and thrombosis: role of integrins and their ligands. Transfus Apher Sci 28:3 (2003), 257–264.
12. 12 Bergmeier, W, Hynes, RO, Extracellular matrix proteins in hemostasis and thrombosis. Cold Spring Harb Perspect Biol, 4(2), 2012, a005132.
13. 13 Savage, B, Saldivar, E, Ruggeri, ZM, Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84:2 (1996), 289–297.
14. 14 Nieswandt, B, Brakebusch, C, Bergmeier, W, et al. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. The EMBO journal 20:9 (2001), 2120–2130.
15. 15 Bynagari-Settipalli, YS, Cornelissen, I, Palmer, D, et al. Redundancy and interaction of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice. Arteriosclerosis, thrombosis, and vascular biology 34:12 (2014), 2563–2569.
16. 16 Mackman, N, Triggers, targets and treatments for thrombosis. Nature 451:7181 (2008), 914–918.
17. 17 Yang, H, Reheman, A, Chen, P, et al. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost 4:10 (2006), 2230–2237.
18. 18 Ni, H, Denis, CV, Subbarao, S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 106:3 (2000), 385–392.
19. 19 Reheman, A, Yang, H, Zhu, G, et al. Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood 113:8 (2009), 1809–1817.
20. 20 Dunne, E, Spring, CM, Reheman, A, et al. Cadherin 6 has a functional role in platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol 32:7 (2012), 1724–1731.
21. 21 Roberts, HR, Hoffman, M, Monroe, DM, A cell-based model of thrombin generation. Seminars in thrombosis and hemostasis 32:Suppl 1 (2006), 32–38.
22. 22 Sakai, T, Johnson, KJ, Murozono, M, et al. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nature medicine 7:3 (2001), 324–330.
23. 23 Ni, H, Yuen, PS, Papalia, JM, et al. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci U S A 100:5 (2003), 2415–2419.
24. 24 Zhai, Z, Wu, J, Xu, X, et al. Fibrinogen controls human platelet fibronectin internalization and cell-surface retention. J Thromb Haemost 5:8 (2007), 1740–1746.
25. 25 Ni, H, Papalia, JM, Degen, JL, et al. Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood 102:10 (2003), 3609–3614.
26. 26 Cines, DB, Blanchette, VS, Immune thrombocytopenic purpura. N Engl J Med 346:13 (2002), 995–1008.
27. 27 Yougbare, I, Lang, S, Yang, H, et al. Maternal anti-platelet beta3 integrins impair angiogenesis and cause intracranial hemorrhage. J Clin Invest 125:4 (2015), 1545–1556.
28. 28 Li, J, van der Wal, DE, Zhu, L, et al. Fc-independent phagocytosis: implications for IVIG and other therapies in immune-mediated thrombocytopenia. Cardiovascular & hematological disorders drug targets 13:1 (2013), 50–58.
29. 29 Lazarus, AH, Semple, JW, Cines, DB, Innate and adaptive immunity in immune thrombocytopenia. Seminars in hematology 50:Suppl 1 (2013), S68–S70.
30. 30 Li, C, Chen, P, Vadasz, B, et al. Co-stimulation with LPS or Poly I:C markedly enhances the anti-platelet immune response and severity of fetal and neonatal alloimmune thrombocytopenia. Thromb Haemost 110:6 (2013), 1250–1258.
31. 31 Ni, H, Chen, P, Spring, CM, et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 107:7 (2006), 2976–2983.
32. 32 Olsson, B, Andersson, PO, Jernas, M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nature medicine 9:9 (2003), 1123–1124.
33. 33 Chow, L, Aslam, R, Speck, ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood 115:6 (2010), 1247–1253.
34. 34 Yazdanbakhsh, K, Zhong, H, Bao, W, Immune dysregulation in immune thrombocytopenia. Seminars in hematology 50:Suppl 1 (2013), S63–S67.
35. 35 Nishimoto, T, Satoh, T, Simpson, EK, et al. Predominant autoantibody response to GPIb/IX in a regulatory T-cell-deficient mouse model for immune thrombocytopenia. J Thromb Haemost 11:2 (2013), 369–372.
36. 36 Aslam, R, Hu, Y, Gebremeskel, S, et al. Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. Blood 120:10 (2012), 2127–2132.
37. 37 Ma, L, Simpson, E, Li, J, et al. CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia. Blood 126:2 (2015), 247–256.
38. 38 Crow, AR, Lazarus, AH, Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. Journal of pediatric hematology/oncology 25:Suppl 1 (2003), S14–S18.
39. 39 Li, J, van der Wal, DE, Zhu, G, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nature communications, 6, 2015, 7737.
40. 40 Nieswandt, B, Bergmeier, W, Rackebrandt, K, et al. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 96:7 (2000), 2520–2527.
41. 41 Webster, ML, Sayeh, E, Crow, M, et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood 108:3 (2006), 943–946.
42. 42 Peng, J, Ma, SH, Liu, J, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost 12:4 (2014), 497–504.
43. 43 Li, C, Piran, S, Chen, P, et al. The maternal immune response to fetal platelet GPIbalpha causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest 121:11 (2011), 4537–4547.
44. 44 Li, J, Callum, JL, Lin, Y, et al. Severe platelet desialylation in a patient with glycoprotein Ib/IX antibody-mediated immune thrombocytopenia and fatal pulmonary hemorrhage. Haematologica 99:4 (2014), e61–e63.
45. 45 Shao, L, Wu, Y, Zhou, H, et al. Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody. Platelets 26:5 (2015), 495–497.
46. 46 Zeng, Q, Zhu, L, Tao, L, et al. Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbalpha antibodies. American journal of hematology 87:2 (2012), 206–208.
47. 47 Shivdasani, RA, Rosenblatt, MF, Zucker-Franklin, D, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 81:5 (1995), 695–704.
48. 48 Palumbo, JS, Zogg, M, Talmage, KE, et al. Role of fibrinogen- and platelet-mediated hemostasis in mouse embryogenesis and reproduction. J Thromb Haemost 2:8 (2004), 1368–1379.
49. 49 Carramolino, L, Fuentes, J, Garcia-Andres, C, et al. Platelets play an essential role in separating the blood and lymphatic vasculatures during embryonic angiogenesis. Circ Res 106:7 (2010), 1197–1201.
50. 50 Lowe, KL, Finney, BA, Deppermann, C, et al. Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development. Blood 125:24 (2015), 3769–3777.